A Survey to Assess the Incidence and Characteristics of Melanoma in Parkinson's Disease Patients
Confirmed diagnosis Parkinson's disease Patient able and willing to give informed consent
Patient must not be taking any investigational drug at the time of enrollment
unconfirmed, undocumented Parkinson's disease unable to give consent taking any
Type of Study:
Bruce Schwartz, Ph.D.
Teva Neuroscience, Inc.
United States: Food and Drug Administration
- Parkinson's Disease
- Malignant Melanoma
- Parkinson Disease